USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
CAMBRIDGE NEUROSCIENCE
Address:
333 PROVIDENCE HWY
NORWOOD, MA 02062
Phone:
(781) 255-6700
URL:
N/A
EIN:
133319074
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $750,000.00 13
SBIR Phase II $3,326,757.00 7

Award List:

NOVEL SCREENING ASSAY FOR EXCITATORY AMINO ACID ANTAGONISTS

Award Year / Program / Phase:
1988 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
Excitatory amino acids (eaas) are implicated in the pathology of a number of human neurological disorders, including epilepsy, ischemic brain damage, and neurodegenerative diseases such as huntington's disease and alzheimer's disease. the role of eaas in these disorders appears to involve abnormally… More

NOVEL, NEMATODE-SPECIFIC ANTHELMINTICS AND NEMATICIDES

Award Year / Program / Phase:
1988 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

NOVEL, NEMATODE-SPECIFIC ANTHELMINTICS AND NEMATICIDES

Award Year / Program / Phase:
1989 / SBIR / Phase II
Award Amount:
$480,968.00
Agency:
HHS
Principal Investigator:
Abstract:
Our purpose is to develop new nematicides and anthelmintics which are nematode-specific and which have a novel mode of action. our approach involves detailed studies of the nematode receptors for glutamic acid (glu) and 5-hydroxytryptamine (serotonin). phase i includes behavioral and… More

DISUBSTITUTED GUANIDINES--NEW CLASS OF NEUROPRO DRUGS

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

NOVEL GLUTAMATE RECEPTOR ANTAGONISTS FROM SPIDER VENOMS

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

HUMAN HOMOLOGUES OF NEMATODE CELL DEATH GENES

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

DITOLYL GUANIDINE ANALOGS AS ANTIPSYCHOTIC DRUGS

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

DISUBSTITUTED GUANIDINES--NEW CLASS OF NEUROPRO DRUGS

Award Year / Program / Phase:
1990 / SBIR / Phase II
Award Amount:
$499,893.00
Agency:
HHS
Principal Investigator:
Abstract:
The goal of this project is to provide a treatment for neurological conditions, such as epilepsy, stroke, trauma, and a number of neurodegenerative diseases, that involve, or are caused by, excessive excitation of nerve cells by agonists of the nmda subtype of glutamate receptors. experiments have… More

DITOLYL GUANIDINE ANALOGS AS ANTIPSYCHOTIC DRUGS

Award Year / Program / Phase:
1990 / SBIR / Phase II
Award Amount:
$409,655.00
Agency:
HHS
Principal Investigator:
Abstract:
A variety of data, from both animal and human behavioral investigations and receptor studies, implicates the sigma receptor in the actions of certain psychotomimetic drugs (benzomorphan opiates, pcp) and also certain novel antipsychotic drugs under development (rimcazole, remoxipride).… More

NOVEL GLUTAMATE RECEPTOR ANTAGONISTS FROM SPIDER VENOMS

Award Year / Program / Phase:
1990 / SBIR / Phase II
Award Amount:
$500,000.00
Agency:
HHS
Principal Investigator:
Abstract:
The excitatory amino acid (eaa) neurotransmitters, such as glutamate and aspartate, have been implicated in the pathology of a number of neurological disorders, including epilepsy, stroke/anoxia, and neurodegenerative diseases. drugs that antagonize eaa neurotransmission offer a novel approach to… More

NEUROPROTECTIVE ANTAGONISTS OF KAINATE NEUROTOXICITY

Award Year / Program / Phase:
1991 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Andrew Knapp
Abstract:
Pathological overstimulation of receptors for the neurotransmitter l-glutamate is believed to contribute to the death or degeneration of nerve cells that occurs in manyacute and chronic neurological disorders. the goal of this project is to develop a drug treatment which will limit neuronal damage… More

HUMAN HOMOLOGUES OF NEMATODE CELL DEATH GENES

Award Year / Program / Phase:
1992 / SBIR / Phase II
Award Amount:
$500,000.00
Agency:
HHS
Principal Investigator:
Abstract:
The goal of this research is to develop diagnostic reagents and new therapeutics for the cure or prevention of degenerative diseases through the isolation and analysis of human genes implicated in the pathways responsible for cell death. the approach to the identification of these genes involves a… More

STUDY OF GROWTH-ASSOCIATED PROTEINS

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Lee D Margolin
Abstract:
The objective of this project is to examine the molecular changes that underlie spinal cord regeneration in the lamprey. we will identify and isolate novel growth-associated proteins (gaps) derived from the central nervous system that are expressed during the course of normal development and… More

SYNTHETIC NEUROPROTECTIVE GLUTAMATE RELEASE BLOCKERS

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Stanley M Goldin
Abstract:
N/a

SYNTHETIC NEUROPROTECTIVE GLUTAMATE RELEASE BLOCKERS

Award Year / Program / Phase:
1993 / SBIR / Phase II
Award Amount:
$500,000.00
Agency:
HHS
Principal Investigator:
Stanley M Goldin
Abstract:
Neuronal damage in ischemia is initiated by excessive release of glutamate from brain nerve terminals. we have discovered, using novel rapid kinetic methodology developed in the p.1.'s laboratory, that certain substituted guanidines and related compounds are antagonists of calcium-dependent release… More

SYMPTOMATIC TREATMENT OF PERIPHERAL NEUROPATHIES

Award Year / Program / Phase:
1997 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Katragadda, subbarao
Abstract:
N/a

NEUREGULIN ANTAGONISTS FOR CANCER TREATMENT

Award Year / Program / Phase:
1997 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Marchionni, mark a
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase II
Award Amount:
$436,241.00
Agency:
HHS
Principal Investigator:
Jinliang Sui
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Jinliang Sui
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Mark A. Marchionni
Abstract:
Not Available Evolution Enterprises has developed a patent-pending system for genetic programming based on a concise, powerful set of operators which are particularly suitable for evolving programs for mathematical modeling. This system is a genetic programming system